Singulair(R) In Asthma And Allergic Rhinitis (0476-383)

An 8 Week Study to Evaluate the Effectiveness of Adding Montelukast to Inhaled Corticosteroid (ICS) to the ICS/Long-Acting Beta 2-Agonist Therapy in Adult Subjects With Asthma and Allergic Rhinitis

Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis.

Inclusion Criteria:

• Patient is a user of Inhaled Corticosteroid (ICS) or ICS/Long-Acting Beta 2-Agonist (ICS/LABA) at any dosage
• Peak expiratory flow is > or = 80% of predicted value on the day of visit 1
• Uncontrolled as per Canadian asthma consensus guidelines

Exclusion Criteria:

• Unwilling to stop regular use of histamine H1 antagonists for allergic rhinitis symptoms
• Unwilling to stop use of antihistamine eye drops or cromoglycate eye drops or ophthalmic corticosteroid